Complement 3 glomerulopathy Market: Epidemiology, Therapies, Companies, DelveInsight | Novartis Pharmaceuticals, Apellis Pharmaceuticals

Complement 3 glomerulopathy emerging therapies, such as Iptacopan (LNP023), Pegcetacoplan (APL-2), and others, are expected to boost the Complement 3 glomerulopathy Market in the upcoming years.

DelveInsight has launched a new report on "Complement 3 glomerulopathy - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Complement 3 glomerulopathy, historical and forecasted epidemiology as well as the Complement 3 glomerulopathy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Discover about the Complement 3 glomerulopathy market report @ https://www.delveinsight.com/report-store/complement-3-glomerulopathy-c3g-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Some of the key facts of the Complement 3 glomerulopathy Market Report:

In 2023, the Complement 3 Glomerulopathy (C3G) market size across the 7MM was estimated at around USD 35 million and is projected to grow by 2034. This anticipated growth is attributed to an increasing number of diagnosed cases and the launch of new, high-cost therapies.
Due to the absence of approved treatments, the C3G market is currently dominated by off-label medications. Standard treatment options include immunosuppressive drugs, corticosteroids, inhibitors of the renin-angiotensin-aldosterone system (RAAS), and other supportive treatments such as calcineurin inhibitors, additional immunosuppressants, and monoclonal antibodies.
C3G is a rare renal disorder marked by the abnormal accumulation of complement protein C3 in the glomeruli-the kidney's filtration structures. This uncontrolled complement activation triggers inflammation and damages kidney tissues, often leading to proteinuria, declining renal function, and potentially kidney failure.
In 2023, the Complement 3 Glomerulopathy (C3G) treatment market size across the 7MM was estimated at approximately USD 35 million. Among these regions, the United States held the largest share, representing around 73% of the total market compared to the EU4, the UK, and Japan.
In 2023, there were approximately 5,760 diagnosed C3G cases in the 7MM, with the United States accounting for about 60% of these cases, followed by Germany.
In March 2025, Novartis revealed that the FDA had approved oral Fabhalta® (iptacopan) for use in adults with C3 glomerulopathy (C3G) to help lower proteinuria, marking it as the first and only authorized therapy for this rare condition.
Emerging complement-inhibiting therapies, such as iptacopan and pegcetacoplan, are showing promise as potential treatment options for complement-driven diseases like C3G.
In 2023, the total number of diagnosed Complement 3 Glomerulopathy (C3G) cases across the 7MM was approximately 5,760. Within this group, the United States accounted for around 3,372 diagnosed cases.
The adult population is more commonly affected by C3G than children. In Japan, about 85% of C3G cases are among adults, while roughly 15% occur in the pediatric population.
In March 2025, the U.S. Food and Drug Administration (FDA) approved Fabhalta® (iptacopan), developed by Novartis, as the first and only treatment for adults with complement 3 glomerulopathy (C3G) to reduce proteinuria.
Key Complement 3 glomerulopathy companies such as Novartis Pharmaceuticals, Apellis Pharmaceuticals, and others are evaluating new drugs for Complement 3 glomerulopathy to improve the treatment landscape.
Promising Complement 3 glomerulopathy therapies include Iptacopan (LNP023), Pegcetacoplan (APL-2), and others.

Complement 3 glomerulopathy Overview

The term "complement 3 glomerulopathy" (C3G) was formally introduced in 2013 through expert consensus to describe a group of rare kidney disorders caused by abnormal regulation of the complement system. Key clinical signs of C3G include proteinuria (excessive protein in the urine), hematuria (blood in the urine), decreased urine output, low blood protein levels, and swelling in various parts of the body.

C3G falls under the category of glomerular diseases and is defined by the dominant presence of the complement protein C3 in the glomeruli, with little to no immunoglobulin and absence of C1q and C4 deposits. The presence of C3 deposits without significant classical or lectin pathway components points to a malfunction in the alternative complement pathway as the primary disease mechanism. This pattern-C3 deposition without significant immunoglobulin-is the key diagnostic criterion in patients presenting with typical features of glomerulonephritis.

Because C3G is so rare, determining accurate incidence and prevalence rates is difficult. Most available estimates come from small-scale cohort studies, which have limited reliability due to the rarity of the disease.

Complement 3 glomerulopathy Market Outlook

According to the National Kidney Foundation (NKF), C3G stands for complement 3 glomerulopathy, where "C3" refers to a protein in the blood crucial for immune function and disease development, and "G" signifies glomerulopathy, or damage to the kidney's filtering units, the glomeruli. C3G includes two subtypes: dense deposit disease (DDD) and C3 glomerulonephritis (C3GN), which differ in the pattern of kidney damage and inflammation observed under a microscope.

Due to the absence of approved therapies for C3G until recently, treatment has largely relied on off-label medications. Common approaches involve using immunosuppressants with corticosteroids, renin-angiotensin-aldosterone system (RAAS) inhibitors, and other supportive treatments such as calcineurin inhibitors or anti-complement agents like eculizumab.

The C3G treatment landscape is evolving, with a moderately active pipeline. While no therapies have reached phase III trials until recently, several promising candidates are in mid-to-late stages of development. Notable companies advancing C3G therapies include Apellis Pharmaceuticals with pegcetacoplan and Novartis Pharmaceuticals with iptacopan.

Discover how the Complement 3 glomerulopathy market is rising in the coming years @ https://www.delveinsight.com/sample-request/complement-3-glomerulopathy-c3g-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Complement 3 glomerulopathy Emerging Drugs
Iptacopan (LNP023): Novartis Pharmaceuticals
Pegcetacoplan (APL-2): Apellis Pharmaceuticals

Scope of the Complement 3 glomerulopathy Market Report
Study Period: 2020-2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Complement 3 glomerulopathy Companies: Novartis Pharmaceuticals, Apellis Pharmaceuticals, and others
Key Complement 3 glomerulopathy Therapies: Iptacopan (LNP023), Pegcetacoplan (APL-2), and others
Complement 3 glomerulopathy Therapeutic Assessment: Complement 3 glomerulopathy current marketed and Complement 3 glomerulopathy emerging therapies
Complement 3 glomerulopathy Market Dynamics: Complement 3 glomerulopathy market drivers and Complement 3 glomerulopathy market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Complement 3 glomerulopathy Unmet Needs, KOL's views, Analyst's views, Complement 3 glomerulopathy Market Access and Reimbursement

To know what's more in our Complement 3 glomerulopathy report, visit https://www.delveinsight.com/report-store/complement-3-glomerulopathy-c3g-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key benefits of the Complement 3 glomerulopathy Market Report:
Complement 3 glomerulopathy market report covers a descriptive overview and comprehensive insight of the Complement 3 glomerulopathy Epidemiology and Complement 3 glomerulopathy market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan).
The Complement 3 glomerulopathy market report provides insights into the current and emerging therapies.
The Complement 3 glomerulopathy market report provides a global historical and forecasted market covering drug outreach in 7MM.
The Complement 3 glomerulopathy market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Complement 3 glomerulopathy market.

Got queries? Click here to know more about the Complement 3 glomerulopathy market Landscape https://www.delveinsight.com/sample-request/complement-3-glomerulopathy-c3g-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Contents

1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Complement 3 glomerulopathy Patient Share (%) Overview at a Glance
5. Complement 3 glomerulopathy Market Overview at a Glance
6. Complement 3 glomerulopathy Disease Background and Overview
7. Complement 3 glomerulopathy Epidemiology and Patient Population
8. Country-Specific Patient Population of Complement 3 glomerulopathy
9. Complement 3 glomerulopathy Current Treatment and Medical Practices
10. Unmet Needs
11. Complement 3 glomerulopathy Emerging Therapies
12. Complement 3 glomerulopathy Market Outlook
13. Country-Wise Complement 3 glomerulopathy Market Analysis (2020-2034)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Complement 3 glomerulopathy Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Click here to read more about Complement 3 glomerulopathy Market Outlook 2034 https://www.delveinsight.com/report-store/complement-3-glomerulopathy-c3g-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Related Reports:

Complement 3 glomerulopathy Pipeline Insights, DelveInsight

"Complement 3 glomerulopathy Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Complement 3 glomerulopathy market. A detailed picture of the Complement 3 glomerulopathy pipeline landscape is provided, which includes the disease overview and Complement 3 glomerulopathy treatment guidelines.

Contact Info:

Kritika Rehani, Assistant Manager, Marketing & Branding
krehani@delveinsight.com
info@delveinsight.com
www.delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.